Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

DURECT Corporation (DRRX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.8956-0.0782 (-8.03%)
At close: 04:00PM EST
0.8956 0.00 (0.00%)
After hours: 06:03PM EST
Advertisement

DURECT Corporation

10260 Bubb Road
Cupertino, CA 95014-4166
United States
408 777 1417
http://www.durect.com

Sector(s)Healthcare
IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees79

Key Executives

NameTitlePayExercisedYear Born
Dr. James E. Brown D.V.M.Co-Founder, CEO, Pres & Director775.88kN/A1957
Mr. Michael H. ArenbergCFO & Sec.452.94kN/A1970
Ms. Judy R. JoiceSr. VP of Operations & Corp. Quality Assurance406.51kN/A1957
Dr. Norman L. SussmanChief Medical Officer419.68k141.76k1953
Dr. Andrew R. MiksztalVP of Pharmaceutical R&D and Principal ScientistN/AN/AN/A
Mr. Steve Helmer J.D.VP & Chief Patent CounselN/AN/AN/A
Dr. WeiQi LinExec. VP of R&D and Principal ScientistN/AN/AN/A
Ms. Jian Li M.B.A.VP of Fin. & Corp. ControllerN/AN/A1970
Dr. Su Il YumExec. OfficerN/AN/A1939
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops DUR-928, an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid homeostasis, inflammation, and cell survival, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine up to days of in adults. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; Santen Pharmaceutical Co., Ltd.; Sandoz AG; and Gilead Sciences, Inc. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.

Corporate Governance

DURECT Corporation’s ISS Governance QualityScore as of September 26, 2021 is 6. The pillar scores are Audit: 5; Board: 3; Shareholder Rights: 8; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement